Traduire
Le projet EMBOBIO reçoit le prix de l’innovation AP-HM 2022
NEOSTEM : soigner l’encéphalopathie anoxo-ischémique du nouveau-né grâce à la thérapie cellulaire
Spreading safe, cheap embolization around the world
Le CERIMED, une plate-forme d’imagerie transversale, interdisciplinaire et fédératrice
R&D
Located on the Marseille-Timone Campus, CERIMED is an innovative multidisciplinary working environment opened to academics and SME for the development and validation of novel medical imaging techniques and protocols.
Services
CERIMED offers its equipments and knowledge in the form of a range of service offers for academics and industries. Each CERIMED department may contribute to development and validation of your innovative medical imaging techniques and protocols.
Training
Implement a transversal way of learning and training, meeting the various concerned disciplines (physics, biology, medicine, radiopharmacy, ...) and the industry, but also offer a theoretical and practical training to the medical imaging techniques.
Recent Posts
-
Symposium’23 Program
“Innovative drugs & health products,
imaging & theranostics agents –
cell & gene biotherapies”, March 17, 2023, 13:30 - 3e matinée Carnot Star “9-12 Recherche-Industrie” dédiée à l’Imagerie, 17 Mars 2023, 8h30
- FairEmbo en Afrique : “Ce médecin marseillais sauve des femmes avec des bouts de ficelle”
- Webinar: Discover Radiotheranostics in Nuclear Medicine (15 Sept. 2022)
- Le projet EmboBio, développé au CERIMED, a reçu le prix de l’innovation AP-HM 2022
Dernières Publications (5/0)
- Horowitz, T, Tabouret, E, Graillon, T, Salgues, B, Chinot, O, Verger, A et al.. Contribution of nuclear medicine to the diagnosis and management of primary brain tumours. Rev Neurol (Paris). 2023; :. doi: 10.1016/j.neurol.2023.03.002. PubMed PMID:36934021 .
- Ayari, S, Abellard, A, Carayol, M, Guedj, É, Gavarry, O. A systematic review of exercise modalities that reduce pro-inflammatory cytokines in humans and animals’ models with mild cognitive impairment or dementia. Exp Gerontol. 2023;175 :112141. doi: 10.1016/j.exger.2023.112141. PubMed PMID:36898593 .
- Verger, A, Yakushev, I, Albert, NL, van Berckel, B, Brendel, M, Cecchin, D et al.. FDA approval of lecanemab: the real start of widespread amyloid PET use? – the EANM Neuroimaging Committee perspective. Eur J Nucl Med Mol Imaging. 2023; :. doi: 10.1007/s00259-023-06177-5. PubMed PMID:36869178 .
- Horowitz, T, Doche, E, Philip, M, Cammilleri, S, Suissa, L, Guedj, E et al.. Regional brain glucose metabolism is differentially affected by ketogenic diet: a human semiquantitative positron emission tomography. Eur J Nucl Med Mol Imaging. 2023; :. doi: 10.1007/s00259-023-06156-w. PubMed PMID:36867201 .
- Imperiale, A, Jha, A, Meuter, L, Nicolas, GP, Taïeb, D, Pacak, K et al.. The emergence of somatostatin antagonist-based theranostics: Paving the road toward another success?. J Nucl Med. 2023; :. doi: 10.2967/jnumed.123.265406. PubMed PMID:36759198 .